Shamim Ruff has sold stock and made no open-market buys since Sep 2016

Shamim Ruff is a biopharmaceutical executive and board member with more than 30 years of strategic leadership in global regulatory affairs and quality, including service as a Director at Reata Pharmaceuticals Inc. (RETA), where she sat on the Board of Directors until the company’s acquisition by Biogen.( Over the course of her career, she has helped guide multiple companies through major value-creating milestones, serving as Chief Regulatory Affairs Officer at Sarepta Therapeutics, where she built and led the regulatory and quality organizations for rare and infectious disease pipelines, and later as Chief Regulatory Affairs Officer and SVP, Head of Quality Assurance at Stoke Therapeutics, overseeing regulatory strategy for its RNA medicines platform.( In March 2026, she was appointed Chief Regulatory Affairs Officer at NervGen Pharma Corp., responsible for the company’s global regulatory strategy for first‑in‑class neuroreparative therapeutics.(

Ruff’s earlier career includes senior regulatory leadership roles at Sanofi‑Genzyme, Amgen, Abbott Laboratories, and AstraZeneca, spanning rare diseases, oncology, hematology, antivirals, and other therapeutic areas.( In addition to her corporate roles, she has served as Chair of the Development Advisory Board and Strategic Regulatory Advisor to the CEO and NDA submissions team at Soleno Therapeutics, and as a director on the board of The Greater Boston Food Bank.( She holds a B.Sc. in chemistry and biology from the University of Leicester and an M.Sc. in analytical chemistry from Loughborough University in the United Kingdom, and is based in the greater Boston/Cambridge biotech hub.(

Written by Perplexity from public sources.